“Genetic testing is really about the patient, and it is helpful to find out what is the patient’s risk” to a particular disease explained Edmund Pezalla, MD, MPH. He thinks that research in this field—prediction of an individual’s risk for a particular type of cancer such as breast or prostate or colon cancer— is currently in its early stages.
“Genomics, on the other hand is about the tumor itself. The tumor has a different genetic makeup than the patient, and it might actually have a different genetic makeup subsequent to treatment. So a tumor further down the treatment road may be different from where it started,” said Dr Pezalla.
“So genomics is important in that it specifically tells us about the tumor that the patient has and it helps us guide treatment, while genetics is about the patient and it helps us guide screening and other preventive services,” he explained.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More